Literature DB >> 16375676

Antifungal susceptibility testing methods.

M A Pfaller1.   

Abstract

The number of systemically active antifungal agents has increased dramatically in recent years in response to the challenge of invasive mycoses. Additional work is needed to better understand the mechanisms of action of these agents as well as the mechanisms of resistance expressed by the fungal pathogens. Antifungal susceptibility testing has been standardized and refined and now may be considered to play an important role in the management of invasive mycoses. More work is needed to optimize the methods for testing new antifungal agents and for testing pathogens other than Candida. The ongoing efforts and international collaborations designed to address these issues will provide important information that will improve the management of serious fungal infections.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16375676     DOI: 10.2174/138945005774912708

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  7 in total

Review 1.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 2.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

3.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

4.  Pattern of Candida isolates in hospitalized children.

Authors:  Rumpa Saha; Shukla Das Das; Ashwani Kumar; Iqbal R Kaur
Journal:  Indian J Pediatr       Date:  2008-09-04       Impact factor: 1.967

5.  Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-01-10       Impact factor: 5.948

6.  Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs.

Authors:  G N Forrest; K Mankes; M A Jabra-Rizk; E Weekes; J K Johnson; D P Lincalis; R A Venezia
Journal:  J Clin Microbiol       Date:  2006-09       Impact factor: 5.948

7.  Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; J F Meis; I M Gould; W Fu; A L Colombo; E Rodriguez-Noriega
Journal:  J Clin Microbiol       Date:  2007-04-18       Impact factor: 5.948

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.